OBJECTIVE: Seventeen-alpha-hydroxyprogesterone caproate (17-OHPC) reduces recurrent preterm birth (PTB). We hypothesized that single nucleotide polymorphisms in the human progesterone receptor (PGR) affect response to 17-OHPC in the prevention of recurrent PTB.
M
ore than 12% of infants born in the United States are born prematurely (Ͻ37 weeks' gestation), but these infants account for Ͼ70% of neonatal morbidity and mortality. Previous studies have suggested that susceptibility to spontaneous preterm birth (PTB) is inherited. Women who themselves are born preterm have a higher risk of delivering preterm; this risk is inversely correlated with maternal gestational age at birth. 1, 2 Furthermore, the highest risk factor for PTB is a history of a prior PTB. 3 Multiple maternal genetic polymorphisms in a variety of genes have been associated with PTB. [2] [3] [4] African Americans have a higher rate of PTB even when controlling for social and other confounding factors, suggesting that the racial disparity to this complication may have a genetic component. [5] [6] [7] [8] [9] Progesterone is a critical hormone involved with pregnancy maintenance; its absence or relative absence is associated with pregnancy failure, preterm labor, and other poor outcomes. 10, 11 Progesterone has been the focus of several recent investigations of therapeutic modalities for PTB. In 2003, Meis et al 12 published results from a multicenter, prospective, double-blind, randomized controlled trial demonstrating that weekly treatment of 17-alpha-hydroxyprogesterone caproate (17-OHPC) reduces recurrent PTB by approximately one third. It appears that 17-OHPC is most efficacious in prolonging pregnancy in women with a previous early spontaneous PTB (Ͻ34 weeks' gestation). 13 Additional studies have examined other progesterone formulations in various high-risk cohorts and have also shown therapeutic benefit with progesterone. [14] [15] [16] The human progesterone receptor (PGR) is a member of the steroid and thyroid receptor superfamily. The gene encoding this receptor is located on chromosome 11q22-23 and consists of 8 exons. 17 Nuclear PGRs exist primarily as 2 distinct isoforms, PGR-A and PGR-B; both have been found in gestational tissues including the amnion and chorion. 18 Although both PGR-A and 19, 20 Thus, the responsiveness of target tissues to progesterone may depend not only on circulating levels of progesterone but also on the ratio of PGR isoforms. 21, 22 It has also been hypothesized that a relative increase in the ratio of PGR-A to PGR-B may contribute to a functional withdrawal of progesterone and lead to the initiation of labor. 23, 24 PGR polymorphisms have been implicated in several different obstetrical/ gynecological disorders, including ovarian cancer, endometriosis, implantation failure, and recurrent miscarriage. 17, [25] [26] [27] Few previous studies have assessed for a relationship between PGR single nucleotide polymorphisms (SNPs) and PTB. 17, 28 While 17-OHPC clearly works for some women, more than one third of women fail treatment and have a recurrent PTB. The reasons for this variable responsiveness are unknown, but may be secondary to an inability to respond to both endogenous and exogenous progesterone.
Our objective was to determine whether response to 17-OHPC is affected by an individual's PGR genotype. We hypothesize that genetic variation in the PGR contributes to the clinical response to 17-OHPC for the prevention of recurrent PTB.
MATERIALS AND METHODS
This is a secondary analysis of women enrolled from September 1999 through February 2002 in a multicenter, prospective, double-blind, randomized controlled trial of 17-OHPC vs placebo, conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. 12 The trial enrolled 463 women with a singleton gestation who had a history of spontaneous PTB and randomized them to receive either weekly injections of 17-OHPC (n ϭ 310) or placebo (n ϭ 153), beginning at [16] [17] [18] [19] [20] 3/7 weeks' gestation and continuing until 36 6/7 weeks' gestation or delivery. The trial demonstrated a reduction in the rate of recurrent PTB from 54.9% in the placebo group to 36.3% in the treatment group (P Ͻ .001).
Institutional review board approval and subject consent for the original study, as well as future analyses such as this study, were obtained at each of the 19 participating network sites by trained research nurses. 12 This secondary analysis was reviewed by the University of Utah Institutional Review Board and determined to be exempt secondary to deidentification of data and study samples prior to this analysis. As a part of the original trial protocol, maternal saliva Table 1. 29 SDS 2.3 software (Applied Biosystems) was used to automatically determine sample genotypes (autocaller) and generate cluster plots. Genotypes were subsequently manually verified, and SNPs were evaluated for deviation from Hardy-Weinberg equilibrium using the exact test, as previously described. 30 Samples were labeled only with a unique bar-coded study identification number, thus, researchers and laboratory personnel were blinded to all clinical data, including pregnancy outcome and treatment group assignment of the biologic samples. Only personnel at the statistical coordinating center had access to the key linking the study identification number with clinical data.
Because allele frequencies vary between races, women were stratified by self-reported race into 2 groups: African American and Caucasian/Hispanic. Women of other self-reported races were excluded. Allele and genotype frequencies were calculated for each SNP. Logistic regression was performed with PTB Ͻ37 weeks' gestation and very PTB Ͻ32 weeks' gestation as dependent variables. The interaction between PGR genotype and 17-OHPC therapy was evaluated by including an interaction term for these variables in the logistic regression model. Those SNPs identified to have significant treatment-genotype interactions were considered for a limited haplotype analysis. Haplotype phase was estimated using R-package haplo.stats version 1.4.4 (Mayo Clinic, Rochester, MN). Potential confounders (factors known to be associated with PTB), including prepregnancy body mass index (BMI), smoking status, and number of prior preterm deliveries, were controlled for in adjusted models.
Additive, codominant, dominant, and recessive inheritance models were considered. The additive model assumes that having 2 copies of minor allele has twice the effect of having 1 copy, the codominant model assumes that heterozygotes have an increased risk of disease over both homozygote groups, the dominant model assumes that having at least 1 copy of the minor allele is sufficient for disease, and the recessive model assumes that 2 copies of the minor allele are needed for disease. The treatment-genotype interaction was considered significant at P Ͻ .05. The inheritance model with the best P value was considered to be the best-fitting model for the respective SNP and was used to calculate odds ratios (ORs).
As this was an exploratory study, no adjustment to the alpha level was made for multiple comparisons, and all comparisons are reported. However, the false discovery rate (FDR) was calculated to evaluate the proportion of false positives among the identified positives. 31, 32 We used the statistical framework proposed by Tusher et al 33 to calculate FDRs for these identified SNPs. SAS (SAS Institute, Cary, NC) and R (www.r-project. org) were used for the statistical analysis.
RESULTS
DNA was successfully extracted from the stored saliva samples of 388 of 459 women (84.5%) analyzed in the original (Tables 2-5 ). This includes 2 SNPs identified in African Americans (rs471767 and rs578029); both were associated with PTB Ͻ37.0 weeks' gestation. The rs500760 was associated with PTB in Caucasian/Hispanic women Ͻ37.0 weeks' gestation. An additional 3 SNPs in Caucasian/Hispanics (rs503362, rs666553, and rs578029) were associated with PTB Ͻ32.0 weeks' gestation.
To further assess whether the risk of recurrent PTB was dependent on both 17-OHPC administration and PGR genotype, we calculated adjusted OR (aOR) of recurrent PTB. These OR were calculated based on treatment group and allele status for each SNP that reached statistical significance in regression models, using the "best" inheritance model. Women who received the placebo and had the predominant genotype comprised the reference group in each calculation ( Table 6) . As an example, among African American women homozygous for the dominant allele (A) in rs471767, there was a significantly lower odds of prematurity with 17-OHPC compared to placebo (aOR, 0.22; 95% confidence interval [CI], 0.09 -0.51). In contrast, African American women with at least 1 copy of the minor allele (G) had similar rates of prematurity irrespective of treatment received (aOR of PTB with placebo, 0.51; 95% CI, 0.19 -1.37 vs 0.47; 95% CI, 0.20 -1.06 with 17-OHPC). This interaction between the rs471767 genotype and treatment was significant even when controlling for BMI, smoking history, and number of prior PTB (P ϭ .023).
Results from the limited haplotype analysis as described in the methods section are shown in Table 7 . As an example, when the rs471767 rs578029 haplotype block was examined among African American women, it is notable that while all women had a decreased odds of PTB Ͻ37 weeks' gestation with 17-OHPC, those women with the GA haplotype also had a lower odds of PTB when they received placebo ( Table 7 ). The odds of PTB among those with the GA haplotype was seemingly unaffected by treatment (placebo aOR, 0.58; 95% CI, 0.26 -1.29, 17-OHPC aOR, 0.50; 95% CI, 0.22-1.12).
The estimated FDR for the reported SNPs based on the African American group was Ͼ99.9% and 65.1% for SNPs based on the Caucasian/Hispanic group. The FDR applies to all of the reported significant findings, not to individual SNPs. 
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We have demonstrated evidence of a relationship between clinical response to 17-OHPC and PGR polymorphisms. Notably, we found several SNPs in both African American and Caucasian/Hispanic women that appear to alter responsiveness to 17-OHPC. The SNPs studied were selected for comprehensive screening of the large (approximately 200-kilobase long) PGR HapMap haplotype block. The rs471767 SNP is located just upstream (5') of the PGR promoter region. It is plausible that genetic variation in the upstream region of the PGR in the area of rs471767 may alter expression of the PGR gene product, possibly through alterations in the ratio of the PGR-A to B isoform ratio. Carriage of the minor allele for SNP rs471767 has been previously associated with spontaneous PTB in a group of Hispanic and Caucasian patients in Utah, although information regarding supplemental progestin use was not available for those women, and an interaction between progestin use and carriage of the minor allele could not be assessed. 28 Some results seem to indicate an increased odds of PTB with 17-OHPC treatment. For example, Caucasian/Hispanic women who received 17-OHPC and had the GG genotype for rs503362 had a relatively increased odds of (aOR, 2.89; 95% CI, 0.54 -15.6). This is in contrast to those patients with the GC or CC genotypes, whose odds of PTB was higher with placebo (aOR, 2.42; 95% CI, 0.35-16.7), but significantly less with 17-OHPC (aOR, 0.28; 95% CI, 0.02-3.51). When the rs503362 rs666553 haplotype block was examined, Caucasian/Hispanic women with the GC haplotype had a 10-fold higher risk of PTB Ͻ32 weeks' gestation (Table 7) . These patterns follow those noted for the individual SNP analysis. These results indicating increased odds of PTB with 17-OHPC treatment highlight the importance of future study and refinement of a response (or harm) genotype profile to ensure patient safety.
The functional PGR ϩ331 A/G mutation (rs10895068) has been previously shown to alter transcription rates of PGR-B relative to PGR-A, and has been associated with an increased risk of ovarian cancer. 34 We did not observe an interaction between rs10895068 and 17-OHPC prophylaxis. There are several possible reasons for this lack of observation. The ϩ331 A/G mutation may have a different effect on gestational tissues. Alternatively, this mutation may be involved with the PTB phenotype, but not be affected by treatment with 17-OHPC. As inclusion in this study required women to have at least 1 prior spontaneous PTB, our study is not able to detect genetic differences between women with and without a history of PTB.
Previous studies of PGR variation among women with PTB have been limited, and in contrast to this work, have not examined for an interaction among progestin administration, PGR genotype, and PTB. Diaz-Cueto et al 35 studied 4 PGR polymorphisms in 64 preterm patients and 54 control subjects and concluded that polymorphisms in the PGR gene are unlikely to be associated with PTB in a Hispanic population. Guoyang et al 17 genotyped 78 primarily Hispanic women with PTB for 3 PGR SNP and found an association between PGR genotype and PTB in 2 of these SNP but only for women with a BMI Ͻ18.5 kg/ m 2 . However, in 2007, Ehn et al 27 conducted a study of the PGR gene with several notable results. These authors examined 18 SNPs in 415 maternal-fetal infant pairs, and found a relationship between prematurity and SNP rs503362 (P ϭ .008). Similarly, our results support a relationship among SNP rs503362, response to 17-OHPC, and early prematurity (Ͻ32 weeks') among non-African American women. Ehn et al 27 also reported a relationship among SNPs rs653752 and rs4754732 and prematurity; we did not find an association between these polymorphisms and 17-OHPC response.
These study results should be interpreted with certain limitations in mind. This is a secondary analysis and the original study was not designed to detect differences in rates of PGR polymorphisms. We investigated only maternal genotypes; fetal DNA was not available. We did not correct for multiple comparisons, as this study was exploratory. Due to a smaller number of non-African Americans, we grouped Caucasian and Hispanic women for analysis, which may have biased our results. However, prior studies have shown a negligible risk of confounding due to admixture of Caucasian and Hispanic populations. 36 Our sample size was limited, particularly when studying recurrent PTB Ͻ32 weeks' gestation. Furthermore, we cannot infer the mechanism of variable responsiveness to 17-OHPC; plasma levels of progesterone or the metabolism of 17-OHPC may be altered by these polymorphisms in the PGR. Given the complexity of the PTB phenotype, it is likely that other genes also contribute to 17-OHPC responsiveness for the prevention of recurrent PTB.
There are several strengths to our study. Our study cohort consisted of a relatively large number of women with at least one prior spontaneous PTB. Furthermore, current practice recommendations would not support withholding 17-OHPC therapy in women with a history of Ն1 prior spontaneous PTB. 37 Thus, this prospectively collected data set is unique in that we are able to compare genotypes of women at high risk for spontaneous PTB who have received 
